Evidence mapPaperPMID 29061652Full record

ArticleJournal of the American Society of Nephrology : JASN2018

Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.

Shannon M Harlan, Kathleen M Heinz-Taheny, John M Sullivan, Tao Wei, Hana E Baker, Dianna L Jaqua, Zhonghua Qi, Martin S Cramer, Tatiyana L Shiyanova, Matthew D Breyer and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Epigenetics in the pathogenesis of diabetic nephropathy.Acta biochimica et biophysica Sinica · 2022
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shannon M HarlanLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Kathleen M Heinz-TahenyLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
John M SullivanLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Tao WeiLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Hana E BakerLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Dianna L JaquaLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Zhonghua QiLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Martin S CramerLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Tatiyana L ShiyanovaLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Matthew D BreyerLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Josef G HeuerLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana jheuer@lilly.com.
Eli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progress in research and developing therapeutics to prevent diabetic kidney disease (DKD) is limited by a lack of animal models exhibiting progressive kidney disease. Chronic hypertension, a driving factor of disease progression in human patients, is lacking in most available models of diabetes. We hypothesized that superimposition of hypertension on diabetic mouse models would accelerate DKD. To test this possibility, we induced persistent hypertension in three mouse models of type 1 diabetes and two models of type 2 diabetes by adeno-associated virus delivery of renin (ReninAAV). Compared with LacZAAV-treated counterparts, ReninAAV-treated type 1 diabetic Akita/129 mice exhibited a substantial increase in albumin-to-creatinine ratio (ACR) and serum creatinine level and more severe renal lesions. In type 2 models of diabetes (C57BKLS

Indexed as

Disease Models, AnimalAnimalsAntihypertensive AgentsCreatinineDependovirusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleGenetic VectorsHypertensionHypoglycemic AgentsJanus KinasesLac OperonLisinoprilAntihypertensive AgentsCreatinineHypoglycemic AgentsJanus KinasesLisinoprilNitric Oxide Synthase Type IIINos3 protein, mouseReninRosiglitazoneSerum AlbuminSTAT Transcription Factorschronic diabetic complicationsdiabetic glomerulopathydiabetic nephropathyelectron microscopyhypertension

Identifiers

PMID29061652
PMCPMC5791057
OpenAlexW2765479650

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.